Yupelri Not Superior to Spiriva in Phase 4 Trial
Theravance Biopharma's COPD treatment Yupelri was not superior to Boehringer Ingelheim's Spiriva Handihaler, according to results from a phase 4 study reported by Theravance.
Tag: Yupelri revefenacin
All
Latest
Yupelri Not Superior to Spiriva in Phase 4 Trial
Theravance Biopharma’s COPD treatment Yupelri was not superior to Boehringer Ingelheim’s Spiriva Handihaler, according to results from a phase 4 study reported by Theravance.
Read More